The interim phase 2 trial results show a good immune response in participants and the therapy is well tolerated to date.
New cGMP fermentation facility in the UK set to meet growing demand for drug substance production, supporting biopharma ...
The Series D financing will support the clinical development of two ADCs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback